Nanobiotix is developing a way for the company’s locally injected radioenhancer for solid tumors to treat metastasized cancers, in combination with checkpoint inhibitors, and also deliver results distally.
As the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting presents many clinical trial updates, there appears to be a theme: access to drugs and pricing.
Migraine headaches can be reduced in frequency and severity by atopant, an oral therapy developed by AbbVie, according to data presented at the 2021 American Headache Society’s (AHS) Annual Scientific Meeting.
On the cusp of the 2021 American Society of Clinical Oncology meeting, more companies are announcing data presentations that will be made over the four-day conference as BioSpace continues to take a look at some of the data that will be shared.
An immunotherapy showed for the first time it can help early-stage lung cancer patients survive longer without their disease returning, according to data on May 19, a potential turning point for such drugs to be used before tumors spread.
Iovance Biotherapeutics faces another delay in the company’s biologics license application (BLA) submission for lifileucel, as the U.S. Food and Drug Administration once again requested additional data on the tumor-infiltrating lymphocyte (TIL) therapy candidate’s potency assays.
Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) was approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
The Consistent Testing Terminology Working Group published a white paper with industry-wide recommendations for precision medicine testing terms to be utilized in patient education and communication.
Myovant announced additional data from the company’s Phase III HERO trial of once-daily, oral relugolix in advanced prostate cancer.
The American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually this year due to the COVID-19 pandemic and included hundreds of abstracts, posters and presentations.